(NASDAQ: UTHR) United Therapeutics's forecast annual revenue growth rate of 5.39% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
United Therapeutics's revenue in 2025 is $2,994,100,000.On average, 7 Wall Street analysts forecast UTHR's revenue for 2025 to be $145,033,084,090, with the lowest UTHR revenue forecast at $138,339,486,770, and the highest UTHR revenue forecast at $152,158,171,366. On average, 7 Wall Street analysts forecast UTHR's revenue for 2026 to be $151,902,055,961, with the lowest UTHR revenue forecast at $138,133,169,077, and the highest UTHR revenue forecast at $160,704,974,292.
In 2027, UTHR is forecast to generate $157,948,553,667 in revenue, with the lowest revenue forecast at $138,044,309,029 and the highest revenue forecast at $197,249,458,114.